Viridian Therapeutics, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Viridian Therapeutics, Inc./DE (VRDN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $24.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $12.80M, a 9.40% increase year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $11.50M, a 11.65% increase year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $11.70M.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $10.30M.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $41.40M, a 4.55% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $39.60M, a 23.99% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $52.10M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|
| 2026-06-30 | $12.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $24.30M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $11.50M 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | $41.40M 10-K · filed 2026-02-26 | ||
| 2025-06-30 | $11.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.00M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $10.30M 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $39.60M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $52.10M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |